title: Pembrolizumab induced severe sclerodermoid reaction.
authors.affiliation: Divisions of Hematology/Oncology, Mayo Clinic, Rochester, USA.
authors.forename: N
authors.initials: N
authors.lastname: Shenoy
authors.affiliation: Divisions of Hematology/Oncology, Mayo Clinic, Rochester, USA.
authors.forename: B
authors.initials: B
authors.lastname: Esplin
authors.affiliation: Dermatology, Mayo Clinic, Rochester, USA.
authors.forename: N
authors.initials: N
authors.lastname: Barbosa
authors.affiliation: Dermatology, Mayo Clinic, Rochester, USA.
authors.forename: C
authors.initials: C
authors.lastname: Wieland
authors.affiliation: Rheumatology, Mayo Clinic, Rochester, USA.
authors.forename: U
authors.initials: U
authors.lastname: Thanarajasingam
authors.affiliation: Divisions of Hematology/Oncology, Mayo Clinic, Rochester, USA.
authors.forename: S
authors.initials: S
authors.lastname: Markovic
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000139:chemically induced*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab